The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Wairarapa Masonic Village
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
 
Andrea Wang-Gillam
No Relationships to Disclose
 
Richard Hubner
Honoraria - Abbott Nutrition; Ipsen
Consulting or Advisory Role - BTG; Shire
Travel, Accommodations, Expenses - Bayer; Celgene
 
Beloo Mirakhur
Employment - ipsen; ipsen
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Floris de Jong
Employment - Shire
Stock and Other Ownership Interests - Baxalta/Shire; Pharmacyclics
 
Bruce Belanger
Employment - Ipsen; Merrimack
 
Li-Tzong Chen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - Celgene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan